Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:
“Proud to be one of the featured lead authors for one of the five selected abstracts for the Plenary Session at American Society of Clinical Oncology (ASCO) | Dr Andrew Kuykendall presented on behalf of our group , the VERIFY program, a positive randomized Ph3 study of Rusfertide, first-in-class hepcidin mimetic for patients with phlebotomy-dependent Polycythemia Vera (PV).”
More posts featuring Naveen Pemmaraju.
